Compounding Pharmacies Market Size & Share Report, 2032

Compounding Pharmacies Market – By Product (Oral, Parenteral, Topical, Ophthalmic, Nasal, Rectal, Otic) Therapeutic Area (Pain Management, Hormone Replacement), Application, Compounding Type, Sterility, Distribution Channel, Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising geriatric population and improved life expectancy across the globe

3.2.1.2&nbsp;&nbsp;&nbsp; Rising adoption of customized medicine in the developed regions

3.2.1.3&nbsp;&nbsp;&nbsp; Shortage of drugs across the globe

3.2.1.4&nbsp;&nbsp;&nbsp; Benefits of compounded medication

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Lack of skilled lab technicians and pharmacists in developed economies

3.2.2.2&nbsp;&nbsp;&nbsp; High cost of equipment and maintenance of sterile environment

3.2.2.3&nbsp;&nbsp;&nbsp; Volatile regulatory scenario

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; U.S.

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.4.3&nbsp;&nbsp;&nbsp; Australia

3.5&nbsp;&nbsp;&nbsp; Reimbursement landscape

3.5.1&nbsp;&nbsp;&nbsp; U.S.

3.5.2&nbsp;&nbsp;&nbsp; Europe

3.5.3&nbsp;&nbsp;&nbsp; Australia

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Oral

5.2.1&nbsp;&nbsp;&nbsp; Solid preparations

5.2.1.1&nbsp;&nbsp;&nbsp; Tablets

5.2.1.2&nbsp;&nbsp;&nbsp; Capsules

5.2.1.3&nbsp;&nbsp;&nbsp; Granules

5.2.1.4&nbsp;&nbsp;&nbsp; Powder

5.2.1.5&nbsp;&nbsp;&nbsp; Other solid preparations

5.2.2&nbsp;&nbsp;&nbsp; Liquid preparations

5.2.2.1&nbsp;&nbsp;&nbsp; Solutions

5.2.2.2&nbsp;&nbsp;&nbsp; Suspension

5.2.2.3&nbsp;&nbsp;&nbsp; Emulsion

5.2.2.4&nbsp;&nbsp;&nbsp; Syrup

5.2.2.5&nbsp;&nbsp;&nbsp; Other liquid preparations

5.3&nbsp;&nbsp;&nbsp; Topical

5.3.1&nbsp;&nbsp;&nbsp; Ointments

5.3.2&nbsp;&nbsp;&nbsp; Creams

5.3.3&nbsp;&nbsp;&nbsp; Gels

5.3.4&nbsp;&nbsp;&nbsp; Pastes

5.3.5&nbsp;&nbsp;&nbsp; Other topical products

5.4&nbsp;&nbsp;&nbsp; Rectal

5.4.1&nbsp;&nbsp;&nbsp; Suppositories

5.4.2&nbsp;&nbsp;&nbsp; Enema

5.4.3&nbsp;&nbsp;&nbsp; Other rectal products

5.5&nbsp;&nbsp;&nbsp; Parenteral

5.5.1&nbsp;&nbsp;&nbsp; Large volume parenterals (LVPs)

5.5.2&nbsp;&nbsp;&nbsp; Small volume parenterals (LVPs)

5.6&nbsp;&nbsp;&nbsp; Nasal

5.7&nbsp;&nbsp;&nbsp; Ophthalmic

5.8&nbsp;&nbsp;&nbsp; Otic

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapeutic Area, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Pain management

6.3&nbsp;&nbsp;&nbsp; Hormone replacement

6.4&nbsp;&nbsp;&nbsp; Dermatology applications

6.5&nbsp;&nbsp;&nbsp; Specialty drugs

6.6&nbsp;&nbsp;&nbsp; Nutritional supplements

6.7&nbsp;&nbsp;&nbsp; Other therapeutic areas

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Adult

7.3&nbsp;&nbsp;&nbsp; Geriatric

7.4&nbsp;&nbsp;&nbsp; Veterinary

7.5&nbsp;&nbsp;&nbsp; Pediatric

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Compounding Type, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Pharmaceutical ingredient alteration (PIA)

8.3&nbsp;&nbsp;&nbsp; Currently unavailable pharmaceutical manufacturing (CUPM)

8.4&nbsp;&nbsp;&nbsp; Pharmaceutical dosage alteration (PDA)

8.5&nbsp;&nbsp;&nbsp; Other compounding types

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Sterility, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Sterile dosage form

9.3&nbsp;&nbsp;&nbsp; Non sterile dosage form

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

10.3&nbsp;&nbsp;&nbsp; Compounding pharmacies

10.4&nbsp;&nbsp;&nbsp; Other distribution channels

Chapter 11&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

11.1&nbsp;&nbsp;&nbsp; Key trends

11.2&nbsp;&nbsp;&nbsp; North America

11.2.1&nbsp;&nbsp;&nbsp;U.S.

11.2.2&nbsp;&nbsp;&nbsp;Canada

11.3&nbsp;&nbsp;&nbsp; Europe

11.3.1&nbsp;&nbsp;&nbsp;Germany

11.3.2&nbsp;&nbsp;&nbsp;UK

11.3.3&nbsp;&nbsp;&nbsp;France

11.3.4&nbsp;&nbsp;&nbsp;Spain

11.3.5&nbsp;&nbsp;&nbsp;Italy

11.3.6&nbsp;&nbsp;&nbsp;Poland

11.3.7&nbsp;&nbsp;&nbsp;Netherlands

11.3.8&nbsp;&nbsp;&nbsp;Sweden

11.3.9&nbsp;&nbsp;&nbsp;Belgium

11.3.10&nbsp;&nbsp;&nbsp; Rest of Europe

11.4&nbsp;&nbsp;&nbsp; Asia Pacific

11.4.1&nbsp;&nbsp;&nbsp;China

11.4.2&nbsp;&nbsp;&nbsp;Japan

11.4.3&nbsp;&nbsp;&nbsp;India

11.4.4&nbsp;&nbsp;&nbsp;Australia

11.4.5&nbsp;&nbsp;&nbsp;South Korea

11.4.6&nbsp;&nbsp;&nbsp;Singapore

11.4.7&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

11.5&nbsp;&nbsp;&nbsp; Latin America

11.5.1&nbsp;&nbsp;&nbsp;Brazil

11.5.2&nbsp;&nbsp;&nbsp;Mexico

11.5.3&nbsp;&nbsp;&nbsp;Argentina

11.5.4&nbsp;&nbsp;&nbsp;Rest of Latin America

11.6&nbsp;&nbsp;&nbsp; Middle East and Africa

11.6.1&nbsp;&nbsp;&nbsp;South Africa

11.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

11.6.3&nbsp;&nbsp;&nbsp;UAE

11.6.4&nbsp;&nbsp;&nbsp;Qatar

11.6.5&nbsp;&nbsp;&nbsp;Rest of Middle East and Africa

Chapter 12&nbsp;&nbsp;&nbsp;Company Profiles

12.1&nbsp;&nbsp;&nbsp; B. Braun Melsungen AG

12.2&nbsp;&nbsp;&nbsp; Clinigen Group PLC

12.3&nbsp;&nbsp;&nbsp; Dougherty&#39;s Pharmacy, Inc.

12.4&nbsp;&nbsp;&nbsp; Fagron NV

12.5&nbsp;&nbsp;&nbsp; Fresenius Kabi AG

12.6&nbsp;&nbsp;&nbsp; ITC Compounding Pharmacy

12.7&nbsp;&nbsp;&nbsp; Institutional Pharmacy Solutions, LLC

12.8&nbsp;&nbsp;&nbsp; Lorraine&rsquo;s Pharmacy

12.9&nbsp;&nbsp;&nbsp; McGuff Compounding Pharmacy Services

12.10&nbsp;&nbsp;&nbsp; Nephron Pharmaceuticals Corporation

12.11&nbsp;&nbsp;&nbsp; Pencol Compounding Pharmacy

12.12&nbsp;&nbsp;&nbsp; Rx3 Compounding Pharmacy

12.13&nbsp;&nbsp;&nbsp; Triangle Compounding Pharmacies

12.14&nbsp;&nbsp;&nbsp; Valor Compounding Pharmacy, Inc.

12.15&nbsp;&nbsp;&nbsp; Wedgewood Village Pharmacy, Inc. 
&nbsp;

Compounding Pharmacies Market

Customize This Report

Industries

Information

Link

Global Headquarters